Liver metastasis from prostate cancer is uncommon and remains poorly understood.
We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29 %. Eight (29.63 %) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37 %) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan-Meier curves and logrank tests for univariate analysis.
Written by:
Wang H, Li B, Zhang P, Yao Y, Chang J. Are you the author?
Department of Interventional Oncology, Tianjin Cancer Hospital and Institute, Tianjin Medical University, Tianjin, China.
Reference: Tumour Biol. 2013 Aug 20. Epub ahead of print.
doi: 10.1007/s13277-013-1083-6
PubMed Abstract
PMID: 23959476
UroToday.com Prostate Cancer Section
